Background/Aim: Several proteins involved in immune regulation and the relationship
among these, the tumor microenvironment, and clinical outcomes of eribulin treatment were …

Background/Aim: In addition to its cytocidal effects as a microtubule dynamics inhibitor,
eribulin mesylate (eribulin) regulates the tumour microenvironment. We examined the …

Purpose Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative
advanced breast cancer (HER2− ABC) patients; however, the mechanism underlying the OS …

Background: Eribulin mesilate (eribulin), a non-taxane microtubule dynamics inhibitor, has
shown trends towards greater overall survival (OS) compared with progression-free survival …

Background/Aim: Eribulin mesylate (eribulin) is currently used for the treatment of locally
advanced or metastatic breast cancer (MBC). It is a cytotoxic agent with unique mechanisms …

Background Eribulin mesylate (eribulin), a non-taxane microtubule dynamic inhibitor, has
been widely used in the treatment of patients with advanced or metastatic breast cancer. The …

Background Eribulin, a nontaxane synthetic inhibitor of microtubule dynamics, is widely
used to manage locally advanced or metastatic breast cancer (MBC). Eribulin has …

Eribulin is a novel microtubule inhibitor with mitotic and nonmitotic mechanisms of action.
Both pooled and subgroup analyses from large-scale Phase III clinical trials demonstrated …

Simple Summary Eribulin mesylate, an anti-mitotic drug used for the treatment of metastatic
breast cancer (BC), exhibits significant effects on cancer cell migration, invasion, and …

Background The recently developed reagent, eribulin mesylate (eribulin), is a microtubule
dynamics inhibitor with a mechanism of action that differs from those of taxanes and vinca …